Over-the-Counter Monograph User Fees: Stakeholder Meeting, 35965-35966 [2017-16229]
Download as PDF
Federal Register / Vol. 82, No. 147 / Wednesday, August 2, 2017 / Notices
sradovich on DSKBCFCHB2PROD with NOTICES
C. Fee Payment Procedures
1. The preferred payment method is
online using electronic check
(Automated Clearing House (ACH) also
known as eCheck) or credit card
(Discover, VISA, MasterCard, American
Express). Secure electronic payments
can be submitted using the User Fees
Payment Portal at https://
userfees.fda.gov/pay. (Note: Only full
payments are accepted. No partial
payments can be made online.) Once
you search for your invoice, click ‘‘Pay
Now’’ to be redirected to Pay.gov.
Electronic payment options are based on
the balance due. Payment by credit card
is available for balances less than
$25,000. If the balance exceeds this
amount, only the ACH option is
available. Payments must be made using
U.S bank accounts as well as U.S. credit
cards.
2. If paying with a paper check:
Checks must be in U.S. currency from
a U.S. bank and made payable to the
Food and Drug Administration.
Payments can be mailed to: Food and
Drug Administration, P.O. Box 979033,
St. Louis, MO 63197–9000. If a check is
sent by a courier that requests a street
address, the courier can deliver the
check to: U.S. Bank, Attn: Government
Lockbox 979033, 1005 Convention
Plaza, St. Louis, MO 63101. (Note: This
U.S. Bank address is for courier delivery
only. If you have any questions
concerning courier delivery, contact the
U.S. Bank at 314–418–4013).
3. When paying by wire transfer, the
invoice number must be included.
Without the invoice number the
payment may not be applied. Regarding
re-inspection fees, if the payment
amount is not applied, the invoice
amount will be referred to collections.
The originating financial institution
may charge a wire transfer fee. If the
financial institution charges a wire
transfer fee, it is required that the
outsourcing facility add that amount to
the payment to ensure that the invoice
is paid in full. Use the following
account information when sending a
wire transfer: New York Federal Reserve
Bank, U.S. Dept of Treasury, TREAS
NYC, 33 Liberty St., New York, NY
10045, Acct. No. 75060099, Routing No.
021030004, SWIFT: FRNYUS33,
Beneficiary: FDA, 8455 Colesville Rd.,
14th Floor, Silver Spring, MD 20993–
0002. If needed, FDA’s tax identification
number is 53–0196965.
Dated: July 25, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–16185 Filed 8–1–17; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
19:43 Aug 01, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Over-the-Counter Monograph User
Fees: Stakeholder Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public meeting.
The Food and Drug
Administration (FDA) will hold a
webinar for stakeholders on August 23,
2017, to provide stakeholders with a
status update on the process of FDA and
industry discussions on an Over-theCounter (OTC) Monograph user fee
program that began in July 2016. FDA
will also provide an overview of
proposed performance goals and
procedures related to a potential new
OTC monograph user fee program. This
webinar is intended to be a followup to
the June 10, 2016, public meeting and
the September 6, 2016, stakeholder
webinar on a potential new OTC
monograph user fee program.
DATES: FDA will hold a webinar for
stakeholders on Wednesday, August 23,
2017, from 12:30 p.m. to 2 p.m. EDT.
FOR FURTHER INFORMATION CONTACT:
Mary Vienna, Office of Executive
Programs, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20903–0002,
301–796–4150, email:
OTCMonographUserFeeProgram@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Introduction
On June 10, 2016, FDA held a public
meeting on a potential new user fee
program for nonprescription (over-thecounter or OTC) monograph drugs. In
the announcement of the public meeting
in the Federal Register (May 11, 2016,
81 FR 29275), FDA invited public
comment as the Agency considers a
user-fee program for OTC monograph
drugs. A user-fee program would
provide funding to supplement
congressional non-user-fee
appropriations, and would support
timely and efficient FDA review of the
efficacy and safety of ingredients
included in or proposed for inclusion in
a monograph. Interested persons were
given until July 11, 2016, to submit
comments. A stakeholder webinar was
held on September 6, 2016, which
provided stakeholders with a status
update on the process of FDA and
industry discussions that began in July
2016. In the notice of public meeting
(August 8, 2016, 81 FR 52444), FDA
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
35965
invited public comments and interested
parties were given until October 6, 2016,
to submit comments.
FDA will hold a webinar for
stakeholders on August 23, 2017, to
provide stakeholders with a status
update on the process of FDA and
industry discussions on an OTC
Monograph user fee program that began
in July 2016. FDA will also provide an
overview of proposed performance goals
and procedures related to a potential
new OTC monograph user fee program.
This webinar is intended to be a
followup to the June 10, 2016, public
meeting and the September 6, 2016,
stakeholder webinar on a potential new
OTC monograph user fee program.
II. Background
Meeting minutes from FDA and
industry discussions on a new OTC
monograph user fee program can be
found at: https://www.fda.gov/
ForIndustry/UserFees/
OTCMonographUserFee/default.htm.
The proposed OTC Monograph User Fee
Program Performance Goals and
Procedures—Fiscal Years 2018–2022
document can also be found at that
same Web site.
Additional background information
on OTC monograph drugs (such as how
OTC drugs can be marketed, and the
differences between marketing through
approved applications and marketing
under the monographs), factors FDA
considers important in developing a
user-fee program, and the questions for
which FDA asked the public to consider
and provide input, can be found in the
Federal Register notice from the June
10, 2016, public meeting (https://
www.federalregister.gov/articles/2016/
05/11/2016-11098/over-the-countermonograph-user-fees-public-meetingrequest-for-comments). The meeting
transcript, meeting recording, and
presentations from the June 10, 2016,
public meeting, which can serve as
further background information, can be
found at: https://www.fda.gov/
ForIndustry/UserFees/
OTCMonographUserFee/default.htm. A
summary of the September 6, 2016,
stakeholders’ webinar, can also be found
at: https://www.fda.gov/ForIndustry/
UserFees/OTCMonographUserFee/
default.htm.
III. Stakeholder Meeting Participation
FDA is seeking participation at the
webinar by stakeholders, including
scientific and academic experts, health
care professionals, representatives of
patient and consumer advocacy groups,
and representatives of the OTC
monograph industry. Participating in
the webinar is free. The webinar format
E:\FR\FM\02AUN1.SGM
02AUN1
35966
Federal Register / Vol. 82, No. 147 / Wednesday, August 2, 2017 / Notices
will include presentations by FDA staff
and an opportunity for stakeholders to
ask questions. If you wish to attend the
webinar, FDA asks that you please
register through Eventbrite by 12 a.m.
EDT, Saturday, August 19, 2017: https://
www.eventbrite.com/e/over-the-countermonograph-user-fees-stakeholdermeeting-registration-33593404778. FDA
will email the registered attendees a
URL to join the webinar at least 1 day
before the meeting.
Dated July 27, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–16229 Filed 8–1–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0007]
Animal Drug User Fee Rates and
Payment Procedures for Fiscal Year
2018
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
rates and payment procedures for fiscal
year (FY) 2018 animal drug user fees.
The Federal Food, Drug, and Cosmetic
Act (the FD&C Act), as amended by the
Animal Drug User Fee Amendments of
2013 (ADUFA III), authorizes FDA to
collect user fees for certain animal drug
applications and supplements, for
certain animal drug products, for certain
establishments where such products are
made, and for certain sponsors of such
animal drug applications and/or
investigational animal drug
submissions. This notice establishes the
fee rates for FY 2018.
FOR FURTHER INFORMATION CONTACT: Visit
FDA’s Web site at https://www.fda.gov/
ForIndustry/UserFees/AnimalDrugUser
FeeActADUFA/default.htm or contact
Lisa Kable, Center for Veterinary
Medicine (HFV–10), Food and Drug
SUMMARY:
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–402–6888.
For general questions, you may also
email the Center for Veterinary
Medicine (CVM) at: cvmadufa@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 740 of the FD&C Act (21
U.S.C. 379j–12) establishes four
different types of user fees: (1) Fees for
certain types of animal drug
applications and supplements; (2)
annual fees for certain animal drug
products; (3) annual fees for certain
establishments where such products are
made; and (4) annual fees for certain
sponsors of animal drug applications
and/or investigational animal drug
submissions (21 U.S.C. 379j–12(a)).
When certain conditions are met, FDA
will waive or reduce fees (21 U.S.C.
379j–12(d)).
For FY 2014 through FY 2018, the
FD&C Act establishes aggregate yearly
base revenue amounts for each fiscal
year (21 U.S.C. 379j–12(b)(1)). Base
revenue amounts established for years
after FY 2014 are subject to adjustment
for inflation and workload (21 U.S.C.
379j–12(c)). Fees for applications,
establishments, products, and sponsors
are to be established each year by FDA
so that the percentages of the total
revenue that are derived from each type
of user fee will be as follows: Revenue
from application fees shall be 20 percent
of total fee revenue; revenue from
product fees shall be 27 percent of total
fee revenue; revenue from establishment
fees shall be 26 percent of total fee
revenue; and revenue from sponsor fees
shall be 27 percent of total fee revenue
(21 U.S.C. 379j–12(b)(2)).
For FY 2018, the animal drug user fee
rates are: $238,100 for an animal drug
application; $119,050 for a
supplemental animal drug application
for which safety or effectiveness data are
required and for an animal drug
application subject to the criteria set
forth in section 512(d)(4) of the FD&C
Act (21 U.S.C. 360b(d)(4)); $6,175 for an
annual product fee; $88,750 for an
annual establishment fee; and $75,150
for an annual sponsor fee. FDA will
issue invoices for FY 2018 product,
establishment, and sponsor fees by
December 31, 2017, and payment will
be due by January 31, 2018. The
application fee rates are effective for
applications submitted on or after
October 1, 2017, and will remain in
effect through September 30, 2018.
Applications will not be accepted for
review until FDA has received full
payment of application fees and any
other animal drug user fees owed under
the Animal Drug User Fee program
(ADUFA program).
II. Revenue Amount for FY 2018
A. Statutory Fee Revenue Amounts
ADUFA III, Title I of Public Law 113–
14, specifies that the aggregate fee
revenue amount for FY 2018 for all
animal drug user fee categories is
$21,600,000 (21 U.S.C. 379j–
12(b)(1)(B)).
B. Inflation Adjustment to Fee Revenue
Amount
The fee revenue amount established
in ADUFA III for FY 2015 and
subsequent fiscal years are subject to an
inflation adjustment (21 U.S.C. 379j–
12(c)(2)).
The component of the inflation
adjustment for payroll costs shall be one
plus the average annual percent change
in the cost of all personnel
compensation and benefits (PC&B) paid
per full-time equivalent position (FTE)
at FDA for the first three of the four
preceding fiscal years, multiplied by the
proportion of PC&B costs to total FDA
costs for the first three of the four
preceding fiscal years (see 21 U.S.C.
379j–12(c)(2)(A) and (B)). The data on
total PC&B paid and numbers of FTE
paid, from which the average cost per
FTE can be derived, are published in
FDA’s Justification of Estimates for
Appropriations Committees.
Table 1 summarizes that actual cost
and FTE data for the specified fiscal
years, and provides the percent change
from the previous fiscal year and the
average percent change over the first of
the 4 fiscal years preceding FY 2018.
The 3-year average is 2.2354 percent.
TABLE 1—FDA PERSONNEL COMPENSATION AND BENEFITS (PC&B) EACH YEAR AND PERCENT CHANGE
sradovich on DSKBCFCHB2PROD with NOTICES
Fiscal year
2014
Total PC&B ..............................................................................
Total FTE .................................................................................
PC&B per FTE .........................................................................
Percent Change from Previous Year ......................................
VerDate Sep<11>2014
19:43 Aug 01, 2017
Jkt 241001
PO 00000
Frm 00041
$2,054,937,000
14,555
$141,184
2.3451%
Fmt 4703
Sfmt 4703
2015
$2,232,304,000
15,484
$144,168
2.1136%
E:\FR\FM\02AUN1.SGM
2016
$2,414,728,159
16,381
$147,408
2.2474%
02AUN1
3-Year average
..............................
..............................
..............................
2.2354%
Agencies
[Federal Register Volume 82, Number 147 (Wednesday, August 2, 2017)]
[Notices]
[Pages 35965-35966]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-16229]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Over-the-Counter Monograph User Fees: Stakeholder Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) will hold a webinar for
stakeholders on August 23, 2017, to provide stakeholders with a status
update on the process of FDA and industry discussions on an Over-the-
Counter (OTC) Monograph user fee program that began in July 2016. FDA
will also provide an overview of proposed performance goals and
procedures related to a potential new OTC monograph user fee program.
This webinar is intended to be a followup to the June 10, 2016, public
meeting and the September 6, 2016, stakeholder webinar on a potential
new OTC monograph user fee program.
DATES: FDA will hold a webinar for stakeholders on Wednesday, August
23, 2017, from 12:30 p.m. to 2 p.m. EDT.
FOR FURTHER INFORMATION CONTACT: Mary Vienna, Office of Executive
Programs, Center for Drug Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave., Silver Spring, MD 20903-0002,
301-796-4150, email: OTCMonographUserFeeProgram@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Introduction
On June 10, 2016, FDA held a public meeting on a potential new user
fee program for nonprescription (over-the-counter or OTC) monograph
drugs. In the announcement of the public meeting in the Federal
Register (May 11, 2016, 81 FR 29275), FDA invited public comment as the
Agency considers a user-fee program for OTC monograph drugs. A user-fee
program would provide funding to supplement congressional non-user-fee
appropriations, and would support timely and efficient FDA review of
the efficacy and safety of ingredients included in or proposed for
inclusion in a monograph. Interested persons were given until July 11,
2016, to submit comments. A stakeholder webinar was held on September
6, 2016, which provided stakeholders with a status update on the
process of FDA and industry discussions that began in July 2016. In the
notice of public meeting (August 8, 2016, 81 FR 52444), FDA invited
public comments and interested parties were given until October 6,
2016, to submit comments.
FDA will hold a webinar for stakeholders on August 23, 2017, to
provide stakeholders with a status update on the process of FDA and
industry discussions on an OTC Monograph user fee program that began in
July 2016. FDA will also provide an overview of proposed performance
goals and procedures related to a potential new OTC monograph user fee
program. This webinar is intended to be a followup to the June 10,
2016, public meeting and the September 6, 2016, stakeholder webinar on
a potential new OTC monograph user fee program.
II. Background
Meeting minutes from FDA and industry discussions on a new OTC
monograph user fee program can be found at: https://www.fda.gov/ForIndustry/UserFees/OTCMonographUserFee/default.htm. The proposed OTC
Monograph User Fee Program Performance Goals and Procedures--Fiscal
Years 2018-2022 document can also be found at that same Web site.
Additional background information on OTC monograph drugs (such as
how OTC drugs can be marketed, and the differences between marketing
through approved applications and marketing under the monographs),
factors FDA considers important in developing a user-fee program, and
the questions for which FDA asked the public to consider and provide
input, can be found in the Federal Register notice from the June 10,
2016, public meeting (https://www.federalregister.gov/articles/2016/05/11/2016-11098/over-the-counter-monograph-user-fees-public-meeting-request-for-comments). The meeting transcript, meeting recording, and
presentations from the June 10, 2016, public meeting, which can serve
as further background information, can be found at: https://www.fda.gov/ForIndustry/UserFees/OTCMonographUserFee/default.htm. A
summary of the September 6, 2016, stakeholders' webinar, can also be
found at: https://www.fda.gov/ForIndustry/UserFees/OTCMonographUserFee/default.htm.
III. Stakeholder Meeting Participation
FDA is seeking participation at the webinar by stakeholders,
including scientific and academic experts, health care professionals,
representatives of patient and consumer advocacy groups, and
representatives of the OTC monograph industry. Participating in the
webinar is free. The webinar format
[[Page 35966]]
will include presentations by FDA staff and an opportunity for
stakeholders to ask questions. If you wish to attend the webinar, FDA
asks that you please register through Eventbrite by 12 a.m. EDT,
Saturday, August 19, 2017: https://www.eventbrite.com/e/over-the-counter-monograph-user-fees-stakeholder-meeting-registration-33593404778. FDA will email the registered attendees a URL to join the
webinar at least 1 day before the meeting.
Dated July 27, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-16229 Filed 8-1-17; 8:45 am]
BILLING CODE 4164-01-P